153 related articles for article (PubMed ID: 35526519)
41. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
[TBL] [Abstract][Full Text] [Related]
42. Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion.
Landman Y; Ilouze M; Wein S; Neiman V; Yerushalmi R; Yakimov M; Ku N; Schrock AB; Ali S; Peled N
Clin Breast Cancer; 2018 Jun; 18(3):e267-e270. PubMed ID: 29233640
[No Abstract] [Full Text] [Related]
43. Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
Cloughesy TF; Petrecca K; Walbert T; Butowski N; Salacz M; Perry J; Damek D; Bota D; Bettegowda C; Zhu JJ; Iwamoto F; Placantonakis D; Kim L; Elder B; Kaptain G; Cachia D; Moshel Y; Brem S; Piccioni D; Landolfi J; Chen CC; Gruber H; Rao AR; Hogan D; Accomando W; Ostertag D; Montellano TT; Kheoh T; Kabbinavar F; Vogelbaum MA
JAMA Oncol; 2020 Dec; 6(12):1939-1946. PubMed ID: 33119048
[TBL] [Abstract][Full Text] [Related]
44. Advanced magnetic resonance imaging to support clinical drug development for malignant glioma.
Kassubek R; Müller HP; Thiele A; Kassubek J; Niessen HG
Drug Discov Today; 2021 Feb; 26(2):429-441. PubMed ID: 33249294
[TBL] [Abstract][Full Text] [Related]
45. Use of statins or NSAIDs and survival of patients with high-grade glioma.
Seliger C; Schaertl J; Gerken M; Luber C; Proescholdt M; Riemenschneider MJ; Leitzmann MF; Hau P; Klinkhammer-Schalke M
PLoS One; 2018; 13(12):e0207858. PubMed ID: 30507932
[TBL] [Abstract][Full Text] [Related]
46. Invasion is not an independent prognostic factor in high-grade glioma.
Narayana A; Perretta D; Kunnakkat S; Gruber D; Golfinos J; Parker E; Medabalmi P; Zagzag D; Pat Eagan RN; Gruber M
J Cancer Res Ther; 2011; 7(3):331-5. PubMed ID: 22044816
[TBL] [Abstract][Full Text] [Related]
47. Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study.
Briggs A; Paracha N; Rosettie K; Upton A; Bokemeyer C; Lassen U; Sullivan SD
Oncology; 2022; 100(2):124-130. PubMed ID: 34844255
[TBL] [Abstract][Full Text] [Related]
48. Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting.
van Opijnen MP; Broekman MLD; Cuppen E; Dubbink HJ; Ter Elst A; van Eijk R; Mühlebner A; Jansen C; van der Geize R; Speel EM; Groenen PJTA; de Vos FYF; Wesseling P; de Leng WWJ; Maas SLN
J Neurooncol; 2024 Feb; 166(3):485-492. PubMed ID: 38285243
[TBL] [Abstract][Full Text] [Related]
49. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
50. MiR-634 sensitizes glioma cells to temozolomide by targeting CYR61 through Raf-ERK signaling pathway.
Tan Z; Zhao J; Jiang Y
Cancer Med; 2018 Mar; 7(3):913-921. PubMed ID: 29473317
[TBL] [Abstract][Full Text] [Related]
51. Durable Response to Larotrectinib in a Child With Histologic Diagnosis of Recurrent Disseminated Ependymoma Discovered to Harbor an
Mangum R; Reuther J; Bertrand KC; Chandramohan R; Kukreja MK; Paulino AC; Muzny D; Hu J; Gibbs RA; Curry DJ; Malbari F; Chintagumpala MM; Adesina AM; Fisher KE; Mack SC; Plon SE; Roy A; Parsons DW; Lin FY
JCO Precis Oncol; 2021; 5():. PubMed ID: 34651095
[No Abstract] [Full Text] [Related]
52. Targeting Wee1 for the treatment of pediatric high-grade gliomas.
Mueller S; Hashizume R; Yang X; Kolkowitz I; Olow AK; Phillips J; Smirnov I; Tom MW; Prados MD; James CD; Berger MS; Gupta N; Haas-Kogan DA
Neuro Oncol; 2014 Mar; 16(3):352-60. PubMed ID: 24305702
[TBL] [Abstract][Full Text] [Related]
53. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.
de Groot JF; Lamborn KR; Chang SM; Gilbert MR; Cloughesy TF; Aldape K; Yao J; Jackson EF; Lieberman F; Robins HI; Mehta MP; Lassman AB; Deangelis LM; Yung WK; Chen A; Prados MD; Wen PY
J Clin Oncol; 2011 Jul; 29(19):2689-95. PubMed ID: 21606416
[TBL] [Abstract][Full Text] [Related]
54. Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial.
Narita Y; Muragaki Y; Kagawa N; Asai K; Nagane M; Matsuda M; Ueki K; Kuroda J; Date I; Kobayashi H; Kumabe T; Beppu T; Kanamori M; Kasai S; Nishimura Y; Xiong H; Ocampo C; Yamada M; Mishima K
Cancer Sci; 2021 Dec; 112(12):5020-5033. PubMed ID: 34609773
[TBL] [Abstract][Full Text] [Related]
55. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.
Kummar S; Berlin J; Mascarenhas L; van Tilburg CM; Geoerger B; Lassen UN; Schilder RJ; Turpin B; Nanda S; Keating K; Childs BH; Chirila C; Laetsch TW; Hyman DM; Drilon A; Hong DS
Curr Probl Cancer; 2021 Dec; 45(6):100734. PubMed ID: 33865615
[TBL] [Abstract][Full Text] [Related]
56. Glioma targeted therapy: insight into future of molecular approaches.
Yang K; Wu Z; Zhang H; Zhang N; Wu W; Wang Z; Dai Z; Zhang X; Zhang L; Peng Y; Ye W; Zeng W; Liu Z; Cheng Q
Mol Cancer; 2022 Feb; 21(1):39. PubMed ID: 35135556
[TBL] [Abstract][Full Text] [Related]
57.
Jones KA; Bossler AD; Bellizzi AM; Snow AN
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30936198
[TBL] [Abstract][Full Text] [Related]
58. Temozolomide in the treatment of recurrent malignant glioma.
Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD
Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879
[TBL] [Abstract][Full Text] [Related]
59. Emerging drugs for malignant glioma.
Mason WP
Expert Opin Emerg Drugs; 2008 Mar; 13(1):81-94. PubMed ID: 18321150
[TBL] [Abstract][Full Text] [Related]
60. Mixed response and mechanisms of resistance to larotrectinib in metastatic carcinoma ex pleomorphic adenoma of the parotid harboring an NTRK2 fusion: A case report.
Pircher M; Briner HR; Bonomo M; Horcic M; Petrausch U; Helbling D; Winder T
Medicine (Baltimore); 2021 Jan; 100(4):e24463. PubMed ID: 33530256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
